Luminex Awaits FDA Decision on RVP as Flu Season Looms; Q3 Revenues Rise 55 Percent | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
As flu season rapidly approaches in the US and Europe, Luminex is still awaiting US Food and Drug Administration clearance of its multiplex respiratory virus panel that it had hoped to have on the market this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.